LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Maria Victoria Mateos*, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michele Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytfeld, Emanuele Angelucci, Aurore Perrot, Reuben Benjamin, Niels W.C.J. van de Donk, Enrique M. Ocio, Christof Scheid, Francesca Gay, Wilfried Roeloffzen, Paula Rodriguez-Otero, Annemiek BroijlAnna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M. Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesus San-Miguel, Pieter Sonneveld, Hermann Einsele, Philippe Moreau

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

91 Citations (Scopus)
32 Downloads (Pure)

Abstract

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Original languageEnglish
Pages (from-to)1371-1376
Number of pages6
JournalLeukemia
Volume36
Issue number5
Early online date24 Mar 2022
DOIs
Publication statusPublished - May 2022

Bibliographical note

Funding Information: This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc. Medical writing support was provided by Julie Nowicki, PhD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC.

Publisher Copyright: © 2022, The Author(s).

Fingerprint

Dive into the research topics of 'LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this